Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806553 | 0.90 | GCGR (0.43) | BRD4HDAC1HDAC2GCGRITK | |
| SCHEMBL23807102 | 0.82 | GCGR (0.39) | BRD4HDAC1HDAC2GCGRRXRA | |
| SCHEMBL23807637 | 0.82 | GCGR (0.37) | CNR2BRD4HDAC1HDAC2GCGR | |
| SCHEMBL23788113 | 0.77 | HDAC1 (0.46) | BRD4HDAC1HDAC2RXRARXRB | |
| SCHEMBL23945589 | 0.77 | HDAC1 (0.47) | BRD4HDAC1HDAC2HDAC8RXRA | |
| SCHEMBL23788065 | 0.76 | HDAC1 (0.48) | BRD4HDAC1HDAC2HDAC8RXRA | |
| SCHEMBL23806478 | 0.75 | HDAC1 (0.45) | BRD4HDAC1HDAC2HDAC8GCGR | |
| SCHEMBL23807111 | 0.70 | BRD4 (0.42) | BRD4HDAC1HDAC2HDAC8RXRA | |
| SCHEMBL21996985 | 0.69 | HDAC1 (0.43) | BRD4HDAC1HDAC2HDAC8RXRA | |
| SCHEMBL21997736 | 0.66 | HDAC1 (0.41) | BRD4HDAC1HDAC2HDAC8GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CNR2 2856/4885BRD4 132/4885HDAC1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.